NADIA ELSAYED: Open Payments
NPI 1821314659 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,199 in 11 payments from 10 companies in 2025. Trend: 2023 $1,822 · 2024 $600 · 2025 $1,199
Food & beverage: $1,199
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 2 | $226 |
| COLOPLAST CORP | 1 | $167 |
| GENZYME CORPORATION | 1 | $129 |
| Calliditas Therapeutics US Inc. | 1 | $125 |
| UCB, Inc. | 1 | $115 |
| AstraZeneca Pharmaceuticals LP | 1 | $103 |
| Sage Therapeutics, LLC | 1 | $100 |
| Edwards Lifesciences Corporation | 1 | $96 |
| Novo Nordisk Inc | 1 | $87 |
| KYOWA KIRIN, INC. | 1 | $52 |
Products named: Titan, FABRAZYME, QULIPTA, TARPEYO, Fintepla, LOKELMA, VRAYLAR, SAPIEN 3 Ultra RESILIA.
Industry payments across LA — which companies pay providers there.
